Atlas Trials

A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Clinical trial NCT06161584 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06161584
Sponsor
Apellis Pharmaceuticals, Inc.
Status
ACTIVE_NOT_RECRUITING
Study type
OBSERVATIONAL
Geographic Atrophy
Start date
2023-09-28
Primary completion
2027-06-01
Enrollment
300

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.